Dr. Loda received his M.D. summa cum laude at the University of Milan, Italy. He is a physician-scientist, Professor of Pathology at Harvard Medical School, an independent investigator at Dana Farber Cancer Institute, Associate Member of the Broad Institute and senior surgical pathologist at the Brigham & Women’s Hospital in Boston. Dr. Loda conceived, built and directs a state of the art Center for Molecular Oncologic Pathology at the Dana Farber Cancer Institute. Dr. Loda is one of the pioneer molecular pathologists in the world and has discovered, and explored the mechanism of function of several important cancer biomarkers. His basic research is focused on prostate cancer carcinogenesis and his most important accomplishments include the definition of cell lineage in the prostate in a blastocyst complementation murine model; the discovery of targeted ubiquitination and inactivation of the cyclin dependent kinase inhibitor p27 in human cancer; the discovery of the role of a de-ubiquitinating enzyme (USP2a) in stabilizing a key metabolic enzyme, subsequently proving that this enzyme (Fatty Acid Synthase) is a “metabolic oncogene”. This led, most recently, to the discovery of specific metabolomic profiles associated with driving oncogenes in genetically engineered prostate cells, transgenic mice and human tumors.